CliffBio
small molecule

NAMENDA XR

MEMANTINE HYDROCHLORIDE

Loss of exclusivitySeptember 2029latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameNAMENDA XR
Active ingredientMEMANTINE HYDROCHLORIDE
Strength14MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2010
Marketing statusDISCN

Listed patents

PatentExpiresType
8039009*PEDSeptember 2029—
8039009March 2029use U-539

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NAMENDA XR patent cliff — loss of exclusivity September 2029 | CliffBio